Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

 Functional dyspepsia is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms.

Functional Dyspepsia Signs and Symptoms 

Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals.

Functional Dyspepsia Epidemiology

According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalence of 10–20%. It affects the gastrointestinal tract. The community prevalence of dyspepsia is typically rated in 20% to 40%, and the disorder estimates 3% to 5% of primary care visits.

Endoscopic research was found to assess the Functional Dyspepsia epidemiology and the recently suggested subgroups of meal-related symptoms and epigastric pain. Of the 1033 subjects, 156 had dyspepsia, and of these, 114 had Functional Dyspepsia. Of the 114 subjects with Functional Dyspepsia, nearly 70% had meal-related symptoms (postprandial fullness and early satiation), and 50% had epigastric discomfort. Around 16% had meal-related symptoms and epigastric Pain; this was fewer than expected by chance alone.

Functional Dyspepsia Treatment Options

Functional dyspepsia that is long-lasting and isn't controlled by lifestyle changes may require treatment. The Functional Dyspepsia treatment depends on your signs and symptoms. Treatment may combine medications with behavior therapy.

Medicines that may help manage the signs and symptoms of functional dyspepsia include over-the-counter gas remedies, medications to reduce acid production, medications that block acid 'pumps,' antibiotics, low-dose antidepressants, prokinetics, medications to relieve nausea (antiemetics).

Functional Dyspepsia Market 

Limited late-stage pipeline activities have been observed in Functional Dyspepsia; besides, most of the trials are either completed, suspended or terminated as per ClinicalTrials.gov. Key players, such as Zeria Pharmaceutical, RaQualia Pharma, ISOThrive, Jiangxi Qingfeng Pharmaceutical, and others, are developing a treatment for functional dyspepsia. 

It is worth mentioning that companies like Johnson & Johnson, Yuhan Corporation, Ironwood Pharmaceuticals, Abide Therapeutics, and several others tried investigating drugs for this indication, but then again faced challenges like recruitment issues [For example; Abide Therapeutics (ABX-1431); Ironwood Pharmaceuticals (IW-9179)]. Yuhan Corporation was also investigating YH12852 in patients with Functional Dyspepsia in phase II clinical trials, however, suspended due to dose re-selection.

In addition, Dong-A Socio Group tried extending its reach across global markets. The company also filed for an IND (Investigational New Drug) application for a phase II clinical trial in the United States for Motilitone. It is a phytomedicine for Functional Dyspepsia and Dong-A ST's third new in-house developed original drug. The company initiated a double-blind, placebo-controlled, randomized, 4-week, Phase II Clinical trial for assessment of efficacy and safety of Motilitone in patients with Functional Dyspepsia. This Phase II study is completed. No recent updates are available.

By accessing the scarcity of late-stage pipeline candidates, and the absence of attentiveness by pharmaceutical companies, it can be assumed that Functional Dyspepsia market size will amplify at a moderate rate during the forecast period (2017-2030).